Tanja Obradovic: Ligufalimab plus ivonescimab combined with chemo in the first-line CRC patients

Tanja Obradovic shared a post on LinkedIn:

“Tackling large medical need in microsatellite stable (MSS) colorectal cancer (CRC) with improved therapy is persisting challenge. Are we on the verge of breakthrough in immunotherapy option? Possibly and interesting example of strategic navigation in combo therapy development.

At ESMO 2024 ligufalimab (anti-CD47 monoclonal antibody) plus ivonescimab (anti-VEGF x PD-1 MAb) combined with chemo yielded ORR of 88% in the first-line CRC patients while chemo plus ivonescimab alone resulted in an ORR of 82% (link). This data would argue that in CRC it is likely sufficient to combine ivonescimab with chemo in order to get to best safety-efficacy profile.

No surprise that further development of ligufalimab in combo with ivonescimab appears not to be in CRC despite large indication/medical need but in head and neck cancer (HNSCC) where addition of ligufalimab doubled ORR when added to ivonescimab as the new Ph3 trial posted revealed (link).

Still this is relatively bold move considering small patient sample in the Ph2 but reaching 60% ORR of combo in PDL-1 positive HNSCC is relatively strong initial signal.”

Source: Tanja Obradovic/LinkedIn

More posts featuring Tanja Obradovic on oncodaily.com

Tanja Obradovic is the Vice President of Oncology Scientific Affairs at ICON PLCh. She has over 20 years of clinical research experience and has led major pharmaceutical companies for 13 years. Her research focuses on small molecules, antibodies, cell and gene therapy, and major immunotherapy of PD1 inhibitors.